See the DrugPatentWatch profile for tigecycline

Based on the information available, it is not possible to completely eliminate the liver risks associated with Tigecycline by altering the dosage alone. Tigecycline is an antibiotic used to treat various bacterial infections, and it has been associated with hepatotoxicity, or liver damage [1].

The drug's label includes a black box warning, the most serious type of warning issued by the U.S. Food and Drug Administration (FDA), regarding the risk of hepatotoxicity and death [1]. The label also states that the benefits of Tigecycline should be weighed against the risks of serious adverse reactions, including hepatotoxicity, before prescribing the drug [1].

While adjusting the dosage may help mitigate some of the risks associated with Tigecycline, it is not a complete solution. The FDA recommends monitoring liver function tests in patients receiving Tigecycline, and advises healthcare professionals to discontinue the drug if liver function test abnormalities are detected [1].

In summary, while adjusting the dosage of Tigecycline may help reduce the risk of liver damage, it cannot completely eliminate the risk. Close monitoring of liver function tests and discontinuation of the drug if necessary are crucial to managing the risk of hepatotoxicity associated with Tigecycline.

Sources:
[1] U.S. Food and Drug Administration. Tigecycline (marketed as Tygacil) Information. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tigecycline-marketed-tygacil-information>